CADASIL clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
open to eligible people ages 18 years and up
This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 500 participants will be enrolled and can expect to be on study for up to 5 years.
San Francisco, California and other locations
Our lead scientists for CADASIL research studies include Michael D Geschwind, MD.
Last updated: